TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells
- PMID: 9469414
TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells
Abstract
Macrophages incubated with OVA in the presence of TGF-beta2 induce immune deviation in vivo (impaired delayed hypersensitivity and IgG2a Ab production) when injected into naive, syngeneic mice. OVA-specific TCR transgenic naive T cells (DO11.10 T cells) produce Th1-type cytokines when stimulated in vitro with OVA-pulsed peritoneal exudate cells (PEC), but if PEC are first treated with TGF-beta2 and then pulsed with OVA, the T cells secrete Th2-type cytokines instead. In this study, we investigated the mechanisms that are involved in the modified Ag-presenting functions of macrophages by TGF-beta2 pretreatment. We have found that: 1) TGF-beta2 impaired the capacity of PEC to produce IL-12 and to express CD40; 2) reduced CD40 expression on TGF-beta2-treated PEC impaired IL-12 production when the cells were cocultured with DO11.10 T cells; 3) the failure of TGF-beta2-treated PEC to stimulate DO11.10 T cells to secrete IFN-gamma was due to their impaired IL-12 production. From these results, we conclude that TGF-beta2 treatment impairs the ability of macrophages to produce IL-12 and to express CD40. As a consequence, TGF-beta2-treated PEC fail to promote development of pT cells toward the Th1 phenotype.
Similar articles
-
On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation.Eur J Immunol. 1997 Jul;27(7):1648-56. doi: 10.1002/eji.1830270709. Eur J Immunol. 1997. PMID: 9247573
-
Analysis of in vivo regulatory properties of T cells activated in vitro by TGFbeta2-treated antigen presenting cells.Invest Ophthalmol Vis Sci. 2000 May;41(6):1410-21. Invest Ophthalmol Vis Sci. 2000. PMID: 10798657
-
In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation.Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1803-11. Invest Ophthalmol Vis Sci. 2000. PMID: 10845601
-
Tolerogenic antigen-presenting cells: regulation of the immune response by TGF-beta-treated antigen-presenting cells.Immunol Res. 2004;30(2):155-70. doi: 10.1385/IR:30:2:155. Immunol Res. 2004. PMID: 15477657 Review.
-
Ocular immunosuppressive microenvironment.Chem Immunol. 1999;73:72-89. doi: 10.1159/000058738. Chem Immunol. 1999. PMID: 10590575 Review. No abstract available.
Cited by
-
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20. Mol Ther. 2012. PMID: 22186789 Free PMC article. Clinical Trial.
-
DNA vaccines: influenza virus challenge of a Th2/Tc2 immune response results in a Th2/Tc1 response in the lung.J Virol. 2004 Apr;78(8):4376-80. doi: 10.1128/jvi.78.8.4376-4380.2004. J Virol. 2004. PMID: 15047852 Free PMC article.
-
The anterior chamber of the eye technology and its anatomical, optical, and immunological bases.Physiol Rev. 2024 Jul 1;104(3):881-929. doi: 10.1152/physrev.00024.2023. Epub 2024 Jan 11. Physiol Rev. 2024. PMID: 38206586 Free PMC article. Review.
-
Ups and downs of mucosal cellular immunity against protozoan parasites.Infect Immun. 2001 Jan;69(1):1-8. doi: 10.1128/IAI.69.1.1-8.2001. Infect Immun. 2001. PMID: 11119482 Free PMC article. Review. No abstract available.
-
Studies on delayed systemic effects of ultraviolet B radiation on the induction of contact hypersensitivity, 3. Dendritic cells from secondary lymphoid organs are deficient in interleukin-12 production and capacity to promote activation and differentiation of T helper type 1 cells.Immunology. 2000 Feb;99(2):296-304. doi: 10.1046/j.1365-2567.2000.00951.x. Immunology. 2000. PMID: 10692050 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials